Glucose as a prognostic factor in ovarian carcinoma

Donald M Lamkin; Douglas R Spitz; Mian M K Shahzad; Bridget Zimmerman; Daniel J Lenihan; Koen Degeest; David M Lubaroff; Eileen H Shinn; Anil K Sood; Susan K Lutgendorf

doi:10.1002/cncr.24126

Back

Glucose as a prognostic factor in ovarian carcinoma

Journal article

Open access

Peer reviewed

Glucose as a prognostic factor in ovarian carcinoma

Donald M Lamkin, Douglas R Spitz, Mian M K Shahzad, Bridget Zimmerman, Daniel J Lenihan, Koen Degeest, David M Lubaroff, Eileen H Shinn, Anil K Sood and Susan K Lutgendorf

Cancer, Vol.115(5), pp.1021-1027

03/01/2009

DOI: 10.1002/cncr.24126

PMCID: PMC2649990

PMID: 19156916

Files and links (1)

url

https://doi.org/10.1002/cncr.24126View

Published (Version of record) Open Access

Abstract

Research suggests that glucose levels in cancer patients may be an important prognostic indicator. In ovarian tumors, increased expression of glucose transporter 1 (GLUT1), a transmembrane protein responsible for glucose uptake, is related to shorter survival time in ovarian cancer patients. This study tested the hypothesis that higher presurgical glucose levels predict shorter disease-specific survival time and time to recurrence in ovarian cancer patients. Nonfasting plasma glucose levels were determined for 74 patients with ovarian cancer at the time of their presurgical consultation and for 125 ovarian cancer patients in an independent validation set. Survival time and time to recurrence (disease-free interval [DFI]) were ascertained from medical records. Cox proportional hazards regression models were used to estimate the hazard ratio (HR) for survival time and DFI in relation to glucose level, adjusting for body mass index (BMI), stage, grade, and cytoreduction as appropriate. Higher glucose levels were associated with shorter survival times in univariate analyses (HR, 1.88; P = .05). Multivariate analysis adjusting for stage showed that higher glucose levels were associated with shorter survival times (HR, 2.01; P = .04) and DFI (HR, 2.32; P = .05). In the validation set, higher glucose levels were associated with shorter survival times (HR, 2.01; P = .02) and DFI (HR, 2.48; P = .001) in univariate analysis, although glucose was not independent of the effect of cytoreduction when predicting survival time in this latter set. These findings contribute to mounting evidence that glucose levels have prognostic value in ovarian carcinoma.

Disease-Free Survival

Prognosis

Blood Glucose - analysis

Humans

Middle Aged

Survival Analysis

Ovarian Neoplasms - blood

Adult

Female

Aged

Ovarian Neoplasms - mortality

Preoperative Care

Details

Title: Subtitle: Glucose as a prognostic factor in ovarian carcinoma
Creators: Donald M Lamkin - Department of Psychology, University of Iowa, Iowa City, Iowa 52252, USA
Douglas R Spitz
Mian M K Shahzad
Bridget Zimmerman
Daniel J Lenihan
Koen Degeest
David M Lubaroff
Eileen H Shinn
Anil K Sood
Susan K Lutgendorf
Resource Type: Journal article
Publication Details: Cancer, Vol.115(5), pp.1021-1027
DOI: 10.1002/cncr.24126
PMID: 19156916
PMCID: PMC2649990
NLM abbreviation: Cancer
ISSN: 0008-543X
eISSN: 1097-0142
Publisher: United States
Grant note: R01 CA104825 / NCI NIH HHS R01 CA104825-01 / NCI NIH HHS CF2002-0000832 / PHS HHS R01-CA104825 / NCI NIH HHS K07 CA093512 / NCI NIH HHS R21CA88293 / NCI NIH HHS P30 CA086862 / NCI NIH HHS CA199298 / NCI NIH HHS R21 CA088293 / NCI NIH HHS CA110793 / NCI NIH HHS R01-CA100045 / NCI NIH HHS R01 CA110793 / NCI NIH HHS P50 CA083639 / NCI NIH HHS K07-CA 093512 / NCI NIH HHS P30-CA086862 / NCI NIH HHS R01 CA100045 / NCI NIH HHS
Language: English
Date published: 03/01/2009
Academic Unit: Psychological and Brain Sciences; Pathology; Iowa Neuroscience Institute; Biostatistics; Radiation Oncology; Obstetrics and Gynecology; Urology
Record Identifier: 9983997346502771

Metrics

20 Record Views

51 Times Cited - Web of Science

See more details